Fierce Biotech

Google Cloud introduces digital suite for medical imaging chale Tue, 10/04/2022 - 14:06

Dexcom's G7 diabetes sensor begins European, international debut chale Tue, 10/04/2022 - 12:52

HHS preps for potential pandemics, gives Vir Biotechnology chance to make up to $1B in multiyear contract gmasson Tue, 10/04/2022 - 12:27

With Pfizer sale in the rearview, Biohaven veers toward Kv7 platform following late-stage trial fails, delays mbayer Tue, 10/04/2022 - 11:04

BMS wants light bulb moment, pens deal for access to Autolus’ CAR-T switch gmasson Tue, 10/04/2022 - 10:35

Mission in-Komplete: KalVista axes angioedema program over raised enzyme levels jwaldron Tue, 10/04/2022 - 09:11

Pfizer pulls trigger on Voyager gene therapy capsid deal, clearing it to fire TRACER at CNS disease ntaylor Tue, 10/04/2022 - 08:38

Sanofi spies miRecule therapy, wagering $400M in biobucks to go after muscular dystrophy with RNA ntaylor Tue, 10/04/2022 - 07:54

Flagship-founded Cellarity tacks on $121M series C to fund cell behaviour pipeline mbayer Mon, 10/03/2022 - 17:30

'There are no rules': BMS enters lawless land of molecular degraders with $550M SyntheX deal gmasson Mon, 10/03/2022 - 16:55

PACT unveils teased business venture, sells off select assets and South San Francisco facility to AmplifyBio mbayer Mon, 10/03/2022 - 13:37

Pain relief without opioids' ill effects? Researchers find new molecules hfloersh Mon, 10/03/2022 - 12:50

Northwestern spinout looks to adapt COVID platform for monkeypox tests chale Mon, 10/03/2022 - 11:19

SPAC on track: Preclinical T-cell company Estrella latest in string of biotechs to take blank check route gmasson Mon, 10/03/2022 - 10:23

Roche Diagnostics taps North American head Sause to be next CEO chale Mon, 10/03/2022 - 10:19

Not so Clene break: Biotech’s shares slump 34% on phase 2 ALS flop despite plans to continue testing jwaldron Mon, 10/03/2022 - 10:14

Incyte scoops up preclinical biotech to widen footprint in vitiligo mbayer Mon, 10/03/2022 - 10:07

Spying a devilish deal, AstraZeneca pays 666% premium to buy genomic medicine biotech ntaylor Mon, 10/03/2022 - 08:15

Mesoblast keeps hopes of cell therapy approval alive in latest response to FDA jwaldron Mon, 10/03/2022 - 08:08

After $100M deal, J&J links gene therapy to improved vision in early-phase trial ntaylor Mon, 10/03/2022 - 07:26